Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, Padayatty J, Maw K, Lentell I, Cooke L, Hodson A, Shah N, Sadullah S, Grigoropoulos N, Qian W, Kirkwood AA, Uttenthal BJ, Johnson P, Follows GA. Russell J, et al. Among authors: grigoropoulos n. Ann Hematol. 2021 Apr;100(4):1049-1058. doi: 10.1007/s00277-021-04460-9. Epub 2021 Feb 27. Ann Hematol. 2021. PMID: 33641019 Free PMC article.
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.
Tay T, Somasundaram N, Lim C, Khoo LP, Goh AZK, Lee YS, Liu X, Tao M, Quek R, Farid M, Poon E, Chan JYS, Chang EWY, Yang VSW, Goh YT, Tan D, Diong C, Grigoropoulos NF, Nagarajan C, Poon M, de Mel S, Jeyasekharan A, Chan EHL, Lee J, Chee YL, Lim ST, Tang T. Tay T, et al. Among authors: grigoropoulos nf. Cancer Rep (Hoboken). 2022 Sep;5(9):e1552. doi: 10.1002/cnr2.1552. Epub 2022 Apr 28. Cancer Rep (Hoboken). 2022. PMID: 35481622 Free PMC article.
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.
Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, Low ZS, Prasannan P, Gong C, Tan MGK, Nagarajan C, Huang D, Lu PW, Lim JQ, Barrans S, Ong CK, Lim ST, Chng WJ, Follows G, Hodson DJ, Du MQ, Goh YT, Tan SH, Grigoropoulos NF, Verma NK. Kizhakeyil A, et al. Among authors: grigoropoulos nf. Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0. Mol Cancer. 2021. PMID: 34654425 Free PMC article. No abstract available.
A genomic-augmented multivariate prognostic model for the survival of natural-killer/T-cell lymphoma patients from an international cohort.
Lim JQ, Huang D, Chan JY, Laurensia Y, Wong EKY, Cheah DMZ, Chia BKH, Chuang WY, Kuo MC, Su YJ, Cai QQ, Feng Y, Rao H, Feng LN, Wei PP, Chen JR, Han BW, Lin GW, Cai J, Fang Y, Tan J, Hong H, Liu Y, Zhang F, Li W, Poon MLM, Ng SB, Jeyasekharan A, Ha JCH, Khoo LP, Chin ST, Pang WL, Kee R, Cheng CL, Grigoropoulos NF, Tang T, Tao M, Farid M, Puan KJ, Xiong J, Zhao WL, Khor CC, Hwang W, Kim WS, Campo E, Tan P, Teh BT, Chng WJ, Rötzschke O, Tousseyn T, Huang HQ, Rozen S, Lim ST, Shih LY, Bei JX, Ong CK. Lim JQ, et al. Among authors: grigoropoulos nf. Am J Hematol. 2022 Sep;97(9):1159-1169. doi: 10.1002/ajh.26636. Epub 2022 Jul 5. Am J Hematol. 2022. PMID: 35726449 Free article.
The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, Tang T, Goh AZ, Ghosh A, Ng HJ, Gopalakrishnan S, Loh Y, Lim ST, Hwang W, Tan D, Goh YT. Phipps C, et al. Among authors: grigoropoulos n. Leuk Lymphoma. 2018 Oct;59(10):2336-2341. doi: 10.1080/10428194.2017.1422863. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345210
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng RJ, Wong EKY, Cheah DMZ, Chia BKH, Iqbal J, Grigoropoulos NF, Nairismägi ML, Ng CCY, Rajasegaran V, Hong H, Kim SJ, Cho J, Tse E, Mow B, Cai QC, Poon LM, Cai QQ, Tan J, Chan JY, Lim JX, Goh YT, Phipps C, Rötzschke O, Cheng CL, Ha JCH, Khoo LP, Loh YSM, Au-Yeung R, Chan TS, Kwong YL, Hwang W, Kim WS, Bei JX, Lin T, Ong CK, Lim ST. Lim JQ, et al. Leukemia. 2020 Dec;34(12):3413-3419. doi: 10.1038/s41375-020-1000-0. Epub 2020 Aug 5. Leukemia. 2020. PMID: 32753688 Free PMC article. No abstract available.
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, Ong SY, Xu M; SGHMM1 Investigators; Chng WJ, Goh YT, Nagarajan C. Chen Y, et al. Among authors: grigoropoulos n. Blood Cancer J. 2021 Sep 3;11(9):150. doi: 10.1038/s41408-021-00544-x. Blood Cancer J. 2021. PMID: 34480015 Free PMC article. Clinical Trial. No abstract available.
No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.
Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, Zhe DCM, Saraf SA, Cheng CL, Chuang WY, Kuo MC, Su YJ, Phipps C, Nagarajan C, Lee YS, Lung DTC, Shih LY, Goh YT, Lim ST, Ong CK. Ong SY, et al. Among authors: grigoropoulos n. Haematologica. 2021 Jun 1;106(6):1737-1739. doi: 10.3324/haematol.2020.269209. Haematologica. 2021. PMID: 33054138 Free PMC article. No abstract available.
32 results